UWA-001

UWA-001 is a phenethylamine derivative invented at the University of [Western Australia] as non-toxic alternative to 3,4-methylenedioxy-N-methylamphetamine and researched as a potential treatment for Parkinson's disease.
It has a 5-HT_2A receptor affinity of 1.2 μM, 1.3 μM for the serotonin transporter, 13.4 μM for the norepinephrine transporter and virtually no affinity for the dopamine transporter.
Unlike MDMA and para-methoxyamphetamine, UWA-001 increases prepulse inhibition and was therefore considered to be non-psychoactive, though it was not assayed at other binding sites. It is toxic to the SH-SY5Y cell line at high concentrations, however significantly less toxic than MDMA at all concentrations tested.
UWA-001 is structurally related to the diarylethylamines lefetamine and the dissociative anesthetic ephenidine, which acts as a NMDA receptor antagonist.